NCT04711343View on ClinicalTrials.gov

Comparative Study to Evaluate the Pharmacokinetics of BAT2306 vs Cosentyx® in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

216

Participants

Timeline

Start Date

June 8, 2022

Primary Completion Date

May 3, 2023

Study Completion Date

June 5, 2023

Conditions
Psoriasis
Interventions
DRUG

BAT2306

150mg/1 ml; single dose；prefilled syringe; subcutaneous injection

DRUG

Cosentyx (US-licensed)

150mg/1 ml; single dose；prefilled syringe; subcutaneous injection

DRUG

Cosentyx (EU-licensed)

150mg/1 ml; single dose；prefilled syringe; subcutaneous injection

Trial Locations (1)

Unknown

The First Hospital of Jilin University, Changchun

Sponsors
All Listed Sponsors
lead

Bio-Thera Solutions

INDUSTRY